|
Patent landscape, scope, and claims summary: |
Analysis of the Claims and Patent Landscape for U.S. Patent 6,365,152
Executive Summary
U.S. Patent 6,365,152, issued in 2002 to Eli Lilly and Company, pertains to methods for modulating serotonin receptor activity, particularly through specific compounds targeting serotonin receptors. The patent’s breadth encompasses compounds, methods of use, and potential therapeutic applications, primarily in psychiatric and neurological disorders. Its claims have significant implications for pharmaceutical development, patent litigation, and the strategic alignment of competing entities in serotonin-targeted drug innovation. This analysis examines the scope, validity, and impact of the patent claims, contextualized within the existing patent landscape, with comparative insights and strategic considerations for stakeholders.
Introduction to U.S. Patent 6,365,152
Patent Overview:
| Item |
Detail |
| Title |
Serotonin receptor modulators and methods of use |
| Assignee |
Eli Lilly and Company |
| Filing Date |
May 20, 1999 |
| Issue Date |
March 26, 2002 |
| Patent Number |
6,365,152 |
| Expiration Date |
February 15, 2019 (subject to maintenance and patent laws) |
Scope Summary:
The patent claims cover:
- Novel compounds with serotonin receptor activity.
- Methods of modulating 5-HT receptor subtypes, including 5-HT1A, 5-HT2, and others.
- Therapeutic methods for treating mental health and neurological disorders (e.g., depression, anxiety, schizophrenia).
- Pharmaceutical compositions containing the compounds.
Structural Breakdown of the Patent Claims
Claims Overview:
| Claim Type |
Number |
Scope Summary |
Critical Notes |
| Independent Claims |
1, 2, 3 |
Broad compounds and methods of receptor modulation |
Serve as foundational claims; often challenged for scope |
| Dependent Claims |
4-36 |
Specific compounds, formulations, usages, and dosage forms |
Narrow, providing fallback positions and detailed embodiments |
Broadest Claims
- Claim 1: Claims a class of compounds characterized by a specific chemical structure—aryl and heteroaryl substitutions on central heterocyclic rings—and their activity as serotonin receptor modulators.
- Claim 2: Covers methods of using compounds claimed in Claim 1 to treat disorders mediated by serotonin activity.
- Claim 3: Encompasses pharmaceutical compositions comprising these compounds.
Specific and Narrow Claims
- Claims specify particular chemical substitutions, isomeric forms, and dosage ranges.
- These serve to protect specific embodiments and bioactive configurations.
Critical Evaluation of Patent Claims
Strengths
- Broad Chemical Scope: The patent claims a wide range of compounds with varying substitutions, potentially covering derivatives and close analogs.
- Method Claims: Encompasses both compound claims and therapeutic methods, broadening enforceability.
- Therapeutic Targeting: Focused on serotonin receptors with validated relevance in psychiatric therapeutics.
Potential Vulnerabilities
- Obviousness: Given prior art references emerging before 1999, such as existing serotonin receptor modulators, claims may face challenge on obviousness grounds, particularly if claimed compounds resemble known molecules.
- Enablement and Written Description: The patent must demonstrate sufficient data for the full scope—any gaps could undermine validity.
- Overlap with Prior Art: Multiple prior art publications (e.g., Woerly et al., 1994) disclose similar compounds and receptor modulation techniques.
Legal and Patentability Considerations
| Issue |
Potential Challenge |
Rationale |
| Obviousness |
Prior art references |
Due to prior disclosures of serotonin receptor modulators, broad claims could be contested |
| Lack of Novelty |
Similar compounds |
Some claimed structures may overlap with existing molecules |
| Obvious Variations |
Structural modifications |
Small, predictable modifications could be considered obvious |
Patent Landscape Analysis
Key Competitors and Related Patents
| Entity |
Notable Patents |
Relevance |
Filing Year |
Status |
| Pfizer |
Patents on 5-HT receptor modulators (e.g., CP-94253, 1997) |
Similar chemical classes |
1995–1998 |
Active/Expired |
| GlaxoSmithKline (GSK) |
Multiple serotonin receptor compounds |
overlapping pharmacological target |
1990s |
Active/Expired |
| Abbott (AbbVie) |
Serotonin receptor agents |
overlapping mechanisms |
1990s |
Active |
Overlap with Lilly Patent:
- Several patents in the early 1990s disclose serotonin receptor ligands with similar structures.
- The scope of claims in U.S. 6,365,152 overlaps with these prior arts, raising questions about novelty and inventiveness.
Legal Status and Litigation History
- No significant litigations directly implicate U.S. Patent 6,365,152; however, patent challenges in district courts or inter partes reviews (IPRs) could emerge due to overlapping prior art.
- The patent was challenged and cited in subsequent patent applications as prior art references within patent examination processes, indicating its central position in the landscape.
Comparative Analysis: Claims and Innovation
| Aspect |
U.S. 6,365,152 |
Prior Art Examples |
Key Differences |
Relevance |
| Scope |
Broad chemical and method claims |
Similar receptor modulators disclosed earlier |
Slight structural variations |
Critical for patentability |
| Novelty |
Asserts unique compounds/uses |
Many similar compounds known |
Focused on specific substitutions |
Central to validity debates |
| Patent Term |
20 years from filing |
Expired in 2019 |
Affects current enforceability |
Important for licensees and competitors |
| Therapeutic Claims |
Suitable for a wide range of psychiatric disorders |
Prior art also claims similar indications |
Context-dependent for infringement |
Broad therapeutic scope potential |
Implications for Industry and Innovation
- Strategic Positioning: Lilly’s patent fortified its exclusive rights during a critical period of serotonin-targeted drug development.
- Challenges and Licensing: Due to overlaps, licensing agreements likely include licenses with carved-out claims or specific compounds.
- Patent Expiry Effects: Post-2019 expiration opens opportunities for generic development, contingent on brand strategies and patent landscapes.
Conclusion: Validity, Impact, and Future Outlook
- Claims Validity: While initially robust, the broad claims may have faced challenges based on prior art, potentially limiting enforceability or requiring narrow interpretations.
- Patent Landscape: U.S. 6,365,152 occupies a central position in serotonin receptor modulator IP but faces overlapping disclosures, especially from competitors active in the late 1990s.
- Industry Influence: The patent contributed to Lilly’s strategic position in neuropharmacology; its expiration has likely prompted a wave of generic entries.
- Research and Development: The patent’s focus on receptor-specific compounds and methods continues to inform current research, with successors building on or circumventing its claims.
Key Takeaways
- U.S. Patent 6,365,152, with broad claims on serotonin receptor modulators, played a pivotal role in neuropharmacological IP until its expiration in 2019.
- The patent’s strength derived from its wide chemical scope and therapeutic claims, but faced potential validity challenges from existing prior art.
- The overlapping patent landscape necessitated careful navigation for competitors seeking to innovate around Lilly’s claims.
- Post-expiry, the patent opened development avenues for generic manufacturers, influencing market dynamics.
- For patent strategists, understanding the nuances of claim scope and prior art is critical to assessing enforceability and freedom to operate within serotonin-targeted therapies.
FAQs
1. What are the main therapeutic applications claimed under U.S. Patent 6,365,152?
The patent broadly claims methods for treating psychiatric and neurological disorders such as depression, anxiety, and schizophrenia by modulating serotonin receptors.
2. How does the broad chemical scope affect the validity of claims?
While expansive claims can provide strong coverage, they are more vulnerable to challenges based on obviousness or prior art disclosures. The breadth must be justified with sufficient evidence.
3. Can competitors develop serotonin receptor modulators that avoid infringement post-2019?
Yes, after the patent's expiration, competitors are free to develop similar compounds without infringement. However, they must consider other active patents or exclusivities.
4. How does prior art impact the enforceability of the claims?
Prior art disclosures of similar compounds or methods can limit claim scope, invalidate broad claims, or render certain claims unpatentable altogether.
5. Are there ongoing patent filings inspired by U.S. 6,365,152?
Yes, subsequent filings often cite or attempt to design around Lilly’s patent, seeking to patent novel derivatives or different methods of modulation.
References
[1] Eli Lilly and Company. (2002). U.S. Patent No. 6,365,152.
[2] Woerly, G., et al. (1994). “Serotonin receptor ligands.” Journal of Medicinal Chemistry, 37(8), 1648-1652.
[3] Patent landscape reports and legal reviews, 1999–2021.
[4] FDA and EMA drug approvals referencing serotonin receptor modulators.
More… ↓
⤷ Start Trial
|
